Genkyotex: Disclosure of the total number of voting rights & shares pursuant to Article L. 233-8 II of the French Commercial ...
10 Febbraio 2020 - 5:45PM
Business Wire
(AMF – Autorité des Marchés
Financiers)
Regulatory News:
Genkyotex (Paris:GKTX) (Brussels:GKTX):
Genkyotex shares
ISIN code FR00011790542 –
Euronext Paris & Brussels
Date
Number of shares making up the
share capital
Number of voting
rights
January 31, 2020
9,101,265
Theoretical number of voting
rights(1): 9,101,265
Number of voting rights
exercisable at a shareholders’ meeting(2): 9,087,414
(1) In accordance with Article 223-111 of the AMF’s General
Regulation, this number of shares is calculated based on all shares
carrying the right to vote, including those stripped of voting
rights. (2) Less shares stripped of voting rights.
About Genkyotex Genkyotex is the leading
biopharmaceutical company in NOX therapies, listed on the Euronext
Paris and Euronext Brussels markets. Its unique platform enables
the identification of orally available small-molecules which
selectively inhibit specific NOX enzymes that amplify multiple
disease processes such as fibrosis, inflammation, pain processing,
cancer development, and neurodegeneration. Genkyotex is developing
a pipeline of first-in-class product candidates targeting one or
multiple NOX enzymes. The lead product candidate, setanaxib
(GKT831), a NOX1 and NOX4 inhibitor has shown evidence of
anti-fibrotic activity in a Phase II clinical trial in primary
biliary cholangitis (PBC, a fibrotic orphan disease). Based on its
positive results, a phase 3 trial in PBC is being planned.
setanaxib is also being evaluated in an investigator-initiated
Phase II clinical trial in Type 1 Diabetes and Kidney Disease
(DKD). A grant from the United States National Institutes of Health
(NIH) of $8.9 million was awarded to Professor Victor Thannickal at
the University of Alabama at Birmingham (UAB) to fund a multi-year
research program evaluating the role of NOX enzymes in idiopathic
pulmonary fibrosis (IPF), a chronic lung disease that results in
fibrosis of the lungs, the core component of the program will be to
conduct a Phase 2 trial with the setanaxib in patients with IPF.
This product candidate may also be active in other fibrotic
indications.
Genkyotex also has a versatile platform well-suited to the
development of various immunotherapies (Vaxiclase). A partnership
covering the use of Vaxiclase as an antigen per se (GTL003) has
been established with Serum Institute of India Private Ltd (Serum
Institute), the world’s largest producer of vaccine doses, for the
development by Serum Institute of cellular multivalent combination
vaccines against a variety of infectious diseases.
For further information, please go to www.genkyotex.com
or investors@genkyotex.com
Disclaimer
This press release may contain forward-looking statements by the
company with respect to its objectives. Such statements are based
upon the current beliefs, estimates and expectations of Genkyotex’s
management and are subject to risks and uncertainties such as the
company's ability to implement its chosen strategy, customer market
trends, changes in technologies and in the company's competitive
environment, changes in regulations, clinical or industrial risks
and all risks linked to the company's growth. These factors as well
as other risks and uncertainties may prevent the company from
achieving the objectives outlined in the press release and actual
results may differ from those set forth in the forward-looking
statements, due to various factors. Without being exhaustive, such
factors include uncertainties involved in the development of
Genkyotex’s products, which may not succeed, or in the delivery of
Genkyotex’s products marketing authorizations by the relevant
regulatory authorities and, in general, any factor that could
affects Genkyotex’s capacity to commercialize the products it
develops. No guarantee is given on forward-looking statements which
are subject to a number of risks, notably those described in the
registration document (document de reference) registered by the
French Markets Authority (the AMF) on 26 April 2019 under number
R.19-014, and those linked to changes in economic conditions, the
financial markets, or the markets on which Genkyotex is present.
Genkyotex products are currently used for clinical trials only and
are not otherwise available for distribution or sale.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200210005567/en/
Genkyotex